NCT02286804

Ultherapy for the Treatment of Spider Veins on the Legs

Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Leg Telangiectasia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Ulthera, Inc · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy® treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

Detailed description

This study is a prospective, single center, clinical trial to be conducted at one clinical site. Enrolled subjects will receive up to three Ultherapy® treatments at a single depth, 14 days apart, using a 10-1.5mm transducer. Treatment will be provided along each length of the spider vein and up to four veins will be treated per subject Maximum length of each vein treated is 2cm.

Conditions

• Telangiectasia
• Spider Veins

Interventions

Type	Name	Description
DEVICE	Ultherapy	Micro-focused ultrasound energy delivered below the surface of the skin

Timeline

• Start date: 2014-10-01
• Primary completion: 2015-04-01
• Completion: 2015-05-01
• First posted: 2014-11-10
• Last updated: 2017-12-19

Locations

1 site across 1 country: United States